Tareq Abadl: Irradiated Blood – Safer, Not More Dangerous
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Irradiated Blood – Safer, Not More Dangerous.
Did you know that some blood units are actually irradiated before transfusion… not to harm, but to protect the patient?
What Does ‘Irradiated Blood’ Mean?
When we say a blood unit is irradiated, it means it has been exposed to controlled radiation to inactivate donor T lymphocytes.
Important:
Nothing ‘toxic’ is added to the blood — this is purely a safety modification.
Why Is Irradiation Needed?
The goal is to prevent a rare but serious complication:
Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD)
This happens when:
- Viable donor T cells attack the recipient’s tissues
- Leading to severe, often fatal immune reactions
According to the AABB, irradiation is used to stop donor T cells from proliferating, eliminating this risk.
Which Blood Components Are Irradiated?
Irradiation is mainly used for cellular components, such as:
- Red Blood Cells (RBCs)
- Platelets
Plasma is not irradiated (it doesn’t contain viable lymphocytes).
Beyond ABO and Rh – Smarter Blood Banking
Modern transfusion medicine is not just about matching blood groups:
Blood banks also select specialized products based on patient needs, including:
- Irradiated components
- Washed red cells
- CMV-seronegative units
As highlighted by Canadian Blood Services, these modifications help reduce transfusion-related risks in specific clinical situations.
Does Irradiation Affect the Blood Itself?
Yes – and this is clinically important:
- Reduced shelf life
- Increased potassium levels
- Structural/biochemical changes in cells
Recent updates from AABB emphasize that irradiated products are used only when clearly indicated because of these effects.
Bottom Line
Irradiated blood is not ‘dangerous blood’ – it’s safer blood for the right patient.
In transfusion medicine:
It’s not just about giving blood…
It’s about giving the right product, to the right patient, at the right time.”
Other posts featuring Tareq Abadl on Hemostasis Today.
-
Apr 13, 2026, 12:32Ilenia Calcaterra: Study on Platelet TF–TFPI Imbalance in Hemophilia A Accepted at ISTH 2026
-
Apr 13, 2026, 12:19David Montani: How to Treat Pulmonary Embolism Catheter or Standard Therapy
-
Apr 13, 2026, 12:11Chokri Ben Lamine: Thread Platelet Subpopulations Leads to Therapeutic Implications
-
Apr 13, 2026, 11:49Jecko Thachil: Why Splenectomy Increases Thrombosis Risk and How We Can Prevent It
-
Apr 13, 2026, 11:31Sumyea Kabir: The Hidden Risk of Bombay Blood Group
-
Apr 13, 2026, 10:57José Antonio García Erce: Situation of Immunoglobulins in Spain
-
Apr 13, 2026, 09:51Caitlin Raymond: Jehovah’s Witnesses Can Now Accept Their Own Blood But It Is Still Not That Simple
-
Apr 13, 2026, 09:12We Are Pleased to Welcome Rajneesh Jain as the New Chief Executive Officer – Hemophilia Federation (India)
-
Apr 13, 2026, 08:52Deborah Holzapfel: The Reality for Women with Hemophilia B